BioCentury
ARTICLE | Company News

DRI gets rights to Avanir's Abreva royalties

December 26, 2002 8:00 AM UTC

AVN sold Drug Royalty Corp. (TSE:DRI) a portion of its North American royalty stream on cold sore drug Abreva docosanol 10% cream. AVN received an initial payment of $20.5 million, and is eligible for...